Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Neurology

Navigating Your Options: Treatment Strategies for Schwannoma

At a Glance

Because benign schwannomas grow very slowly, the best treatment focuses on balancing tumor control with preserving your nerve function and quality of life. Patients typically choose between active surveillance, surgical removal, or targeted radiation therapy based on tumor size and symptoms.

Because schwannomas are benign and typically grow very slowly, you often have the luxury of time to weigh your options. The “best” treatment is not always the most aggressive one; instead, the goal is to balance tumor control with the preservation of your quality of life and nerve function [1][2].

Option 1: Active Surveillance (“Watch and Wait”)

For many patients, especially those with small tumors or few symptoms, the first recommendation is often active surveillance. This is not “doing nothing”; it is a proactive strategy of monitoring the tumor closely [3][4].

  • Rationale: Since schwannomas are not cancer and grow slowly, a small tumor may not cause problems for years, or even decades. Some tumors may even stop growing on their own, or in very rare cases, undergo spontaneous shrinkage [5].
  • Protocol: You will typically have a baseline MRI followed by repeat scans at set intervals (e.g., every 6 or 12 months) to document any change in size [3].
  • Quality of Life: Research shows that patients who choose surveillance often maintain a stable quality of life similar to those who undergo immediate treatment [1][6].

Option 2: Microsurgery

Surgery remains the gold-standard treatment for tumors that are large, causing severe symptoms, or compressing critical structures like the spinal cord [7][8].

  • Gross Total Resection (GTR): The goal is often to remove the entire tumor. When successful, this typically provides a permanent cure [9].
  • Subtotal Resection: Because schwannomas are intimately attached to nerves, a surgeon may intentionally leave a tiny sliver of the tumor behind. This “subtotal” approach is used to avoid damaging the nerve and to preserve functions like facial movement or hearing [9][10].
  • When it’s Needed: Surgery is usually prioritized if the tumor is growing rapidly, causing significant muscle weakness, or if it is located in a position where radiation might be less effective [11][12].
  • Risks of Surgery: While highly effective, surgery carries risks, including permanent damage to the nerve being operated on (which could lead to permanent facial palsy or hearing loss), cerebrospinal fluid (CSF) leaks, and infection [10].

Option 3: Stereotactic Radiosurgery (SRS)

Technologies like Gamma Knife or CyberKnife use highly focused beams of radiation to target the tumor without making an incision [13][14].

  • The Goal: Unlike surgery, the goal of SRS is not to make the tumor disappear instantly. Instead, the goal is growth arrest—tricking the tumor cells so they can no longer divide [15][16].
  • How it Works: The precision of SRS allows high doses of radiation to hit the tumor while sparing the healthy surrounding tissue [14][17]. Over time, the tumor may stay the same size or slowly shrink.
  • Advantages: SRS is often associated with better hearing preservation rates for small tumors and a faster return to daily activities compared to surgery [18][19].
  • Risks of Radiosurgery: While non-invasive, SRS carries its own delayed risks, including radiation necrosis (death of healthy tissue), delayed nerve swelling that temporarily worsens symptoms, and progressive hearing loss over several years [16].

Choosing Your Path: A Decision Framework

Your care team will look at several factors to help you decide which strategy fits your life:

Factor Favor Surveillance Favor Radiosurgery (SRS) Favor Microsurgery
Tumor Size Small [4] Small to Medium [20] Large or Compressing [12]
Symptoms None or Mild [3] Mild to Moderate [20] Severe/Progressive [21]
Growth Stable [1] Documented Growth [22] Rapid Growth [11]
Age/Health Any Older/Higher Surgical Risk Younger/Lower Surgical Risk [12]
Primary Goal Avoid Treatment [1] Stop Growth Safely [16] Complete Removal [8]

The choice between these options is often a “shared decision” between you and your specialists, based on which risks you are most comfortable taking [22][23].

Common questions in this guide

What happens if I choose active surveillance for my schwannoma?
Active surveillance, or watching and waiting, involves monitoring your tumor closely with regular MRI scans, usually every 6 to 12 months. Since schwannomas grow slowly, this approach safely avoids treatment side effects for tumors that are small and not causing symptoms.
Will stereotactic radiosurgery make my schwannoma disappear?
The goal of stereotactic radiosurgery, like Gamma Knife, is typically growth arrest rather than making the tumor completely disappear. By targeting the tumor with high doses of radiation, the cells are stopped from dividing, which causes the tumor to stay the same size or slowly shrink over time.
Why would a surgeon intentionally leave part of a schwannoma behind?
Because schwannomas are intimately attached to nerves, a surgeon may perform a subtotal resection, leaving a tiny sliver of the tumor behind. This approach is used intentionally to protect the nerve and preserve vital functions like facial movement and hearing.
What are the main risks of microsurgery for schwannoma?
While highly effective at removing the tumor, microsurgery carries risks such as cerebrospinal fluid leaks, infection, and potential damage to the affected nerve. Depending on the tumor's location, this nerve damage could lead to temporary or permanent facial weakness or hearing loss.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my tumor's size and shape, what is the specific likelihood of it growing within the next 12 to 24 months if we choose active surveillance?
  2. 2.If we choose microsurgery, is the tumor's location conducive to a gross total resection, or might you need to perform a subtotal resection to protect my nerves?
  3. 3.What is your personal 'success rate' for preserving nerve function (like facial movement or hearing) for tumors in this specific location?
  4. 4.If I choose stereotactic radiosurgery, what does 'success' look like on my follow-up scans? Should I expect the tumor to disappear or just stop growing?
  5. 5.What are the risks of 'radiation-induced swelling' after Gamma Knife, and how would that be managed?
  6. 6.If we start with active surveillance and the tumor grows, does that make a future surgery more difficult or risky?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Long-Term Quality of Life of Vestibular Schwannoma Patients: A Longitudinal Analysis.

    Neve OM, Jansen JC, Koot RW, et al.

    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 2023; (168(2)):210-217 doi:10.1177/01945998221088565.

    PMID: 35349360
  2. 2

    Comparing Patient Satisfaction After Upfront Treatment Versus Wait-and-Scan for Small Sporadic Vestibular Schwannoma.

    Nassiri AM, Lohse CM, Tombers NM, et al.

    Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 2023; (44(1)):e42-e47 doi:10.1097/MAO.0000000000003728.

    PMID: 36240733
  3. 3

    Upfront radiation for small, nongrowing vestibular schwannomas: a call for caution.

    Andresen NS, Macielak RJ, Schoo DP, et al.

    Neurosurgical review 2025; (49(1)):18 doi:10.1007/s10143-025-03936-w.

    PMID: 41269367
  4. 4

    Wait-and-scan management in sporadic Koos grade 4 vestibular schwannomas: A longitudinal volumetric study.

    Schouten SM, Cornelissen S, Langenhuizen PPHJ, et al.

    Neuro-oncology advances 2024; (6(1)):vdad144 doi:10.1093/noajnl/vdad144.

    PMID: 38187870
  5. 5

    Spontaneous Volumetric Tumor Regression During Wait-and-Scan Management of 952 Sporadic Vestibular Schwannomas.

    Marinelli JP, Killeen DE, Schnurman Z, et al.

    Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 2022; (43(9)):e1034-e1038 doi:10.1097/MAO.0000000000003651.

    PMID: 36001695
  6. 6

    Long-term Effects of Conservative Management of Vestibular Schwannoma on Dizziness, Balance, and Caloric Function.

    Nilsen KS, Lund-Johansen M, Nordahl SHG, et al.

    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 2019; (161(5)):846-851 doi:10.1177/0194599819860831.

    PMID: 31310582
  7. 7

    Hybrid Benign Peripheral Nerve Sheath Tumors: A Comprehensive Literature Review with Emphasis on Their Clinical, Morphological and Genetic Features.

    Salzano S, Caltabiano R, Zanelli M, et al.

    Diagnostics (Basel, Switzerland) 2025; (15(7)) doi:10.3390/diagnostics15070855.

    PMID: 40218204
  8. 8

    The Long-term Outcome After Resection of Intraspinal Nerve Sheath Tumors: Report of 131 Consecutive Cases.

    Halvorsen CM, Rønning P, Hald J, et al.

    Neurosurgery 2015; (77(4)):585-92; discussion 592-3 doi:10.1227/NEU.0000000000000890.

    PMID: 26191976
  9. 9

    Neurological outcomes and surgical complications in 221 spinal nerve sheath tumors.

    Safaee MM, Lyon R, Barbaro NM, et al.

    Journal of neurosurgery. Spine 2017; (26(1)):103-111 doi:10.3171/2016.5.SPINE15974.

    PMID: 27472744
  10. 10

    Long-Term Hearing Outcome For Vestibular Schwannomas After Microsurgery And Radiotherapy: A Systematic Review and Meta-Analysis.

    Daloiso A, Cazzador D, Concheri S, et al.

    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 2024; (171(6)):1670-1681 doi:10.1002/ohn.910.

    PMID: 39045727
  11. 11

    De Novo Vestibular Schwannoma: A Report of Three Cases.

    Kubota M, Yamakami I, Kubota S, Higuchi Y

    NMC case report journal 2019; (6(2)):47-50 doi:10.2176/nmccrj.cr.2018-0188.

    PMID: 31016100
  12. 12

    Vestibular Schwannomas in Young Patients: A 12-Year Experience in a Single Center.

    Zhang Z, Zheng X, Zhang D, et al.

    World neurosurgery 2022; (158()):e166-e178 doi:10.1016/j.wneu.2021.10.145.

    PMID: 34710579
  13. 13

    The Role of Stereotactic Radiosurgery in Patients With Foramen Magnum Meningiomas.

    Wei Z, Niranjan A, Mehta M, et al.

    Neurosurgery 2026; (98(3)):617-623 doi:10.1227/neu.0000000000003625.

    PMID: 40643252
  14. 14

    Stereotactic radiotherapy for brain metastases of non-small cell lung cancer: A comprehensive review.

    Khan A, Zhao HF, Meng H, et al.

    World journal of radiology 2025; (17(8)):111076 doi:10.4329/wjr.v17.i8.111076.

    PMID: 40901347
  15. 15

    The Effectiveness of Diffusion Tensor Imaging in Determining Radiological Response after Radiosurgery in Patients with Vestibular Schwannoma.

    Cesme DH, Alkan A, Sari L, et al.

    Current medical imaging 2021; (17(5)):602-607 doi:10.2174/1573405617666210127160848.

    PMID: 33504315
  16. 16

    A systematic review and meta-analysis of stereotactic radiosurgery as a primary treatment in fast-growing vestibular schwannomas.

    Shah F, Hamilton LOW, Yiannakis CP, et al.

    The Journal of laryngology and otology 2023; (137(11)):1193-1199 doi:10.1017/S0022215123000786.

    PMID: 37194631
  17. 17

    Perfusion and Volume Response of Canine Brain Tumors to Stereotactic Radiosurgery and Radiotherapy.

    Zwingenberger AL, Pollard RE, Taylor SL, et al.

    Journal of veterinary internal medicine 2016; (30(3)):827-35 doi:10.1111/jvim.13945.

    PMID: 27149650
  18. 18

    Hearing Preservation, Facial Nerve Dysfunction, and Tumor Control in Small Vestibular Schwannoma: A Systematic Review of Gamma Knife Radiosurgery Versus Microsurgery.

    Aman RA, Petonengan DAA, Hafif M, Santoso F

    Journal of clinical neurology (Seoul, Korea) 2023; (19(3)):304-311 doi:10.3988/jcn.2022.0116.

    PMID: 36647227
  19. 19

    Radiosurgery treatment is associated with improved facial nerve preservation versus repeat resection in recurrent vestibular schwannomas.

    Romiyo P, Ng E, Dejam D, et al.

    Acta neurochirurgica 2019; (161(7)):1449-1456 doi:10.1007/s00701-019-03940-2.

    PMID: 31129783
  20. 20

    Treatment options for unilateral vestibular schwannoma: a network meta-analysis.

    Huo X, Zhao X, Liu X, et al.

    BMC cancer 2024; (24(1)):1490 doi:10.1186/s12885-024-13242-1.

    PMID: 39627752
  21. 21

    The Rare Large Common Peroneal Nerve's Schwannoma-A Case Report and Literature Review.

    Harahap R, Harahap ND

    Case reports in oncological medicine 2024; (2024()):9397436 doi:10.1155/2024/9397436.

    PMID: 39262572
  22. 22

    Management of Vestibular Schwannoma (Including NF2): Facial Nerve Considerations.

    Kaul V, Cosetti MK

    Otolaryngologic clinics of North America 2018; (51(6)):1193-1212 doi:10.1016/j.otc.2018.07.015.

    PMID: 30390772
  23. 23

    Clinical practice guideline on the management of vestibular schwannoma.

    Lassaletta L, Acle Cervera L, Altuna X, et al.

    Acta otorrinolaringologica espanola 2024; (75(2)):108-128 doi:10.1016/j.otoeng.2023.10.005.

    PMID: 38346489

This information compares schwannoma treatment options for educational purposes only. Always consult your neurosurgeon or oncologist to determine the safest approach for your specific tumor and anatomy.

Get notified when new evidence is published on Benign schwannoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.